- Canada-based life sciences company Mind Cure Health is pursuing innovative technology and research solutions to improve mental health through technology
- The company is focused on developing digital therapeutics technology and researching psychedelic compounds
- The company’s proprietary software-as-a-service (SaaS) platform iSTRYM is designed to increase transparency and awareness between patients and therapists
- On the research side, Mind Cure Health is also manufacturing synthetic ibogaine and currently determining the commercialization potential of two different pathways for production
- Mind Cure Health recently announced an agreement with experienced clinical psychologist Dr. Ken Weingardt to guide iSTRYM toward near-term commercial deployment
A growing number of researchers in the medical science field are investigating the potential of psychedelic drugs to open a new field of medicinal solutions. Legislators as well as wider segments of society are also beginning to take notice.
Canada-based Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH)
is devoted to building access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. The company has filed a provisional patent application for its pharmaceutical-grade synthetic ibogaine to be used in clinical research and anticipates developing that in conjunction with its software-as-a-service (SaaS) platform iSTRYM, which is designed to help patients and physicians manage psychiatric medications using smart “digital therapeutics” technology.
To further the company’s goals, Mind Cure Health announced Aug. 10 an agreement with Dr. Ken Weingardt in which Weingardt will provide consulting services as a senior clinical technology advisor. Weingardt is a clinical psychologist with 20 years of experience working at the intersection of technology and behavioral health, according to the company (https://ibn.fm/bqm92
Weingardt will guide iSTRYM toward near-term commercial deployment, building clinical excellence in both commercial deployment and design.
“This company is among the first to develop a digital therapeutic specifically designed to support the process of psychedelic-assisted therapy. I am delighted to advise the team as they leverage innovative technologies to potentially reduce symptoms, improve quality of life, and support transformation and healing,” Weingardt stated in the company’s news release.
The company anticipates making iSTRYM available to select clinics during the current Q3 period and launching the software broadly and commercially during the first few months of next year. The product launch will initially be aimed at psychedelic centers but will later expand to integrated clinics, both traditional and psychedelic, and eventually the broader mental health market, according to the company.
Mind Cure Health plans to file for FDA approval under the software as a medical device (“SaMD”) pathway, which it expects to speed reimbursement. iSTRYM will be a fee-based service to help clinics ideally create better care and outcomes for their patients.
Mind Cure Health’s synthetic ibogaine research aims to develop a potential treatment for traumatic brain injury, neuropathic pain and migraines. The company indicates ibogaine may also help repair and rewire the brain’s neural pathways in treating drug addiction.
The company recently announced it had launched the second stage of manufacturing synthetic ibogaine after completing proof-of-concept protocols that tested the chemistry and development route for successfully manufacturing ibogaine. The second stage will focus on the scale-up process by establishing financial models in tandem with assessments of the quality of the synthetic ibogaine to determine the economic viability of commercial scaling (https://ibn.fm/Au7Kn
For more information, visit the company’s website at www.MindCure.com
NOTE TO INVESTORS:
The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire
to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime
. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork